ATAI Life Sciences N.V. Announces 2024 Annual General Meeting of Shareholders
Ticker: ATAI · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: ATAI Life Sciences, Annual Meeting, Proxy Statement, Shareholder Meeting, Hybrid Meeting
TL;DR
<b>ATAI Life Sciences N.V. will host its 2024 hybrid Annual General Meeting on May 17, 2024, offering virtual and in-person attendance options.</b>
AI Summary
ATAI Life Sciences N.V. (ATAI) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. The 2024 Annual General Meeting of Shareholders for ATAI Life Sciences N.V. will be held on May 17, 2024, at 6:00 p.m. CEST. The meeting will be a hybrid event, allowing shareholders to attend virtually or in person in Amsterdam, The Netherlands. Shareholders can attend virtually via www.virtualshareholdermeeting.com/ATAI2024. Questions can be submitted online up to 72 hours in advance of the meeting at www.proxyvote.com. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 22, 2024.
Why It Matters
For investors and stakeholders tracking ATAI Life Sciences N.V., this filing contains several important signals. The hybrid meeting format aims to increase shareholder participation globally by offering both virtual and in-person attendance options. The filing of a Definitive Proxy Statement (DEF 14A) indicates the formal communication to shareholders regarding the upcoming annual meeting and related proposals.
Risk Assessment
Risk Level: low — ATAI Life Sciences N.V. shows low risk based on this filing. The filing is a routine proxy statement for an annual shareholder meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Shareholders should review the proxy materials to understand the proposals being voted on and to participate in the upcoming Annual General Meeting.
Key Numbers
- May 17, 2024 — Annual Meeting Date (2024 Annual General Meeting of Shareholders)
- 6:00 p.m. CEST — Annual Meeting Time (2024 Annual General Meeting of Shareholders)
- 72 hours — Advance Question Submission Window (Shareholders may submit questions up to 72 hours in advance of the meeting)
- 2024 — Meeting Year (2024 Annual General Meeting of Shareholders)
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Registrant name
- May 17, 2024 (date) — Annual General Meeting date
- 6:00 p.m. (Central European Summer Time) (time) — Annual General Meeting time
- Dentons Europe LLP (company) — Location for in-person meeting
- Amsterdam, The Netherlands (location) — Location for in-person meeting
- www.virtualshareholdermeeting.com/ATAI2024 (url) — Virtual meeting link
- www.proxyvote.com (url) — Link for submitting questions
- April 22, 2024 (date) — Filing date
FAQ
When did ATAI Life Sciences N.V. file this DEF 14A?
ATAI Life Sciences N.V. filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ATAI Life Sciences N.V. (ATAI).
Where can I read the original DEF 14A filing from ATAI Life Sciences N.V.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ATAI Life Sciences N.V..
What are the key takeaways from ATAI Life Sciences N.V.'s DEF 14A?
ATAI Life Sciences N.V. filed this DEF 14A on April 22, 2024. Key takeaways: The 2024 Annual General Meeting of Shareholders for ATAI Life Sciences N.V. will be held on May 17, 2024, at 6:00 p.m. CEST.. The meeting will be a hybrid event, allowing shareholders to attend virtually or in person in Amsterdam, The Netherlands.. Shareholders can attend virtually via www.virtualshareholdermeeting.com/ATAI2024..
Is ATAI Life Sciences N.V. a risky investment based on this filing?
Based on this DEF 14A, ATAI Life Sciences N.V. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual shareholder meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading ATAI Life Sciences N.V.'s DEF 14A?
Shareholders should review the proxy materials to understand the proposals being voted on and to participate in the upcoming Annual General Meeting. The overall sentiment from this filing is neutral.
How does ATAI Life Sciences N.V. compare to its industry peers?
ATAI Life Sciences N.V. operates in the pharmaceutical preparations industry, focusing on the development of treatments for mental health conditions.
Are there regulatory concerns for ATAI Life Sciences N.V.?
The filing is a standard proxy statement required by the SEC for public companies holding annual shareholder meetings.
Industry Context
ATAI Life Sciences N.V. operates in the pharmaceutical preparations industry, focusing on the development of treatments for mental health conditions.
Regulatory Implications
The filing is a standard proxy statement required by the SEC for public companies holding annual shareholder meetings.
What Investors Should Do
- Review the proxy statement for details on proposals and voting procedures.
- Register to attend the hybrid Annual General Meeting on May 17, 2024.
- Submit questions in advance via www.proxyvote.com if unable to attend live.
Key Dates
- 2024-05-17: Annual General Meeting of Shareholders — Shareholders will vote on company matters and hear updates.
- 2024-04-22: Filing Date — Definitive Proxy Statement (DEF 14A) filed with the SEC.
Year-Over-Year Comparison
This filing is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual General Meeting, following the typical reporting cycle for such events.
Filing Stats: 4,463 words · 18 min read · ~15 pages · Grade level 10.9 · Accepted 2024-04-22 17:00:43
Filing Documents
- ny20017192x2_def14a.htm (DEF 14A) — 787KB
- logo_atai.jpg (GRAPHIC) — 42KB
- ny20017192x2_pc01.jpg (GRAPHIC) — 674KB
- ny20017192x2_pc02.jpg (GRAPHIC) — 880KB
- sig_cangermayer.jpg (GRAPHIC) — 13KB
- sig_fbrand.jpg (GRAPHIC) — 12KB
- 0001140361-24-021061.txt ( ) — 3020KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 35 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS ​ ​ 37 EXECUTIVE AND DIRECTOR COMPENSATION ​ ​ 39 SHAREHOLDER PROPOSALS ​ ​ 47 OTHER MATTERS ​ ​ 48 SOLICITATION OF PROXIES ​ ​ 48 ANNUAL REPORT ON FORM 10-K ​ ​ 48 i TABLE OF CONTENTS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this proxy statement, other than statements of historical fact, should be considered forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of important factors